Role of levonorgestrel-releasing intrauterine system in dysmenorrhea due to adenomyosis and the influence on ovarian function

Ji F, Fei Ji, Xinhua Yang, Yang XH, Xin-Hua Yang, Aixingzi Aili, Ai Xing Zi AL, Ai Li Ai Xing Zi, HaNiKeZi. TuerXun, Ha Ni Ke Zi TX, Tuer Xun Ha Ni Ke Zi, Yan He, He Y, Yan Ding, Ding Y
Clinical and experimental obstetrics & gynecology · 2014 · vol. 41(6) , pp. 677–680 · doi:10.12891/ceog16682014 · PMID:25566593 · W383640208
article OA: bronze CC0 ⤵ 6 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

The levonorgestrel-releasing intrauterine system effectively alleviated dysmenorrhea in women with adenomyosis and reduced prolactin levels, while minimally impacting ovarian hormone function.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text ⓘ

This clinical study evaluated the efficacy and side-effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) in 60 women with moderate or severe dysmenorrhea associated with adenomyosis diagnosed by transvaginal sonography, assessing dysmenorrhea via a visual analogue scale (VAS), uterine volume, and serum hormone levels (FSH, LH, estradiol, and prolactin) at baseline and 6 and 12 months. After LNG-IUS insertion, dysmenorrhea scores decreased and uterine volume reduced by 6 months, with no statistically significant differences reported for FSH, LH, and estradiol compared with pre-insertion, while prolactin levels markedly declined at both follow-up points. Side-effects were recorded at each visit, but the paper’s limitation as presented is that it is a single-arm, short-term follow-up without a control group, limiting causal inference. This paper is centrally about adenomyosis — specifically, LNG-IUS treatment for adenomyosis-associated dysmenorrhea and effects on ovarian function markers and prolactin.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: The objective of this study was to evaluate the efficacy and side-effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of moderate or severe dysmenorrhea associated with adenomyosis and the influence on ovarian function. STUDY DESIGN: The LNG-IUS was inserted into 60 women who had moderate or severe dysmenorrhea associated with adenomyosis diagnosed by transvaginal sonography. A visual analogue scale (VAS) of dysmenorrhea, uterine volume and serum-levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), etstradiol (E2), and prolactin (PRL) were used to assess the efficacy of the treatment at base- line and at six and 12 months after the LNG-IUS. Serum-levels ofFSH, LH, E2, and PRL were tested in pre-and post-insertion at six and at 12 months, respectively. Side-effects were recorded at every follow-up visit. RESULTS: After six and 12 months of LNG-IUS insertion, dysmenorrhea was obviously alleviated, and the dysmenorrhea scores decreased to 2.6 from 0.6 (p < 0.05). The volume of uterus reduced six months after insertion and later, but without significant change (p 0.01). However, the level of PRL markedly de- clined at six and 12 months after LNG-IUS. CONCLUSION: The LNG-IUS appears to be an effective method in alleviating dysmenorrhea associated with adenomyosis with little effect on ovarian function. It may be helpful to decrease the level of PRL in these patients.
Full text 2,355 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Background: The objective of this study was to evaluate the efficacy and side-effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of moderate or severe dysmenorrhea associated with adenomyosis and the influence on ovarian function. Study Design: The LNG-IUS was inserted into 60 women who had moderate or severe dysmenorrhea associated with adenomyosis diagnosed by transvaginal sonography. A visual analogue scale (VAS) of dysmenorrhea, uterine volume and serum-levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), etstradiol (E2), and prolactin (PRL) were used to assess the efficacy of the treatment at baseline and at six and 12 months after the LNG-IUS. Serum-levels of FSH, LH, E2, and PRL were tested in pre-and post-insertion at six and at 12 months, respectively. Side-effects were recorded at every follow-up visit. Results: After six and 12 months of LNG-IUS insertion, dysmenorrhea was obviously alleviated, and the dysmenorrhea scores decreased to 2.6 from 0.6 (p < 0.05). The volume of uterus reduced six months after insertion and later, but without significant change (p 0.01). However, the level of PRL markedly declined at six and 12 months after LNG-IUS. Conclusion: The LNG-IUS appears to be an effective method in alleviating dysmenorrhea associated with adenomyosis with little effect on ovarian function. It may be helpful to decrease the level of PRL in these patients.

Keywords

- Adenomyosis - Dysmenorrhea - Levonorgestrel-releasing intrauterine system

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

dysmenorrheaadenomyosis

MeSH descriptors

Adenomyosis Dysmenorrhea Intrauterine Devices, Medicated Levonorgestrel Adenomyosis Adult Dysmenorrhea Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Levonorgestrel Luteinizing Hormone Luteinizing Hormone Middle Aged Pain Measurement

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (18)

Cited by (7)

Source provenance

europepmc
last seen: 2026-08-10T06:11:17.106188+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:04.362919+00:00
License: CC0 · commercial use OK